These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
154 related items for PubMed ID: 10725777
1. Serum osteocalcin and insulin-like growth factor I levels in children with congenital adrenal hyperplasia. Hargitai G, Hosszú E, Halász Z, Sólyom J. Horm Res; 1999; 52(3):131-9. PubMed ID: 10725777 [Abstract] [Full Text] [Related]
2. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Völkl TM, Simm D, Beier C, Dörr HG. Pediatrics; 2006 Jan; 117(1):e98-105. PubMed ID: 16396852 [Abstract] [Full Text] [Related]
3. Plasma insulin-like growth factor I levels during treatment of congenital adrenal hyperplasia. Cavallo A, Furlanetto RW, Meyer WJ. Horm Res; 1990 Jan; 34(1):23-6. PubMed ID: 2074088 [Abstract] [Full Text] [Related]
4. Different states of clinical control are associated with changes in IGF-I and IGFBPs in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Cunha HM, Elias LL, Camacho-Hübner C, Moreira AC, Martinelli CE. Clin Endocrinol (Oxf); 2004 Jul; 61(1):94-101. PubMed ID: 15212650 [Abstract] [Full Text] [Related]
5. Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study. Hargitai G, Sólyom J, Battelino T, Lebl J, Pribilincová Z, Hauspie R, Kovács J, Waldhauser F, Frisch H, MEWPE-CAH Study Group. Horm Res; 2001 Jul; 55(4):161-71. PubMed ID: 11598369 [Abstract] [Full Text] [Related]
6. Osteocalcin in congenital adrenal hyperplasia. Lisá L, Neradilová M, Tomásová N, Soutorová M, Zimák J. Bone; 1995 Jan; 16(1):57-9. PubMed ID: 7742084 [Abstract] [Full Text] [Related]
7. Long-term follow-up of children with classic congenital adrenal hyperplasia: suggestions for age dependent treatment in childhood and puberty. Pijnenburg-Kleizen KJ, Thomas CMG, Otten BJ, Roeleveld N, Claahsen-van der Grinten HL. J Pediatr Endocrinol Metab; 2019 Oct 25; 32(10):1055-1063. PubMed ID: 31573958 [Abstract] [Full Text] [Related]
8. The relation of peripubertal and pubertal growth to final adult height in children with classic congenital adrenal hyperplasia. Bomberg EM, Addo OY, Kyllo J, Gonzalez-Bolanos MT, Ltief AM, Pittock S, Himes JH, Miller BS, Sarafoglou K. J Pediatr; 2015 Mar 25; 166(3):743-50. PubMed ID: 25557963 [Abstract] [Full Text] [Related]
9. IGF-I-IGFBP-3-acid-labile subunit (ALS) complex in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH). Völkl TM, Rauh M, Schöfl C, Dörr HG. Growth Horm IGF Res; 2011 Aug 25; 21(4):191-8. PubMed ID: 21636299 [Abstract] [Full Text] [Related]
10. Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life. Bonfig W, Schwarz HP. Horm Res Paediatr; 2011 Aug 25; 75(4):264-8. PubMed ID: 21196707 [Abstract] [Full Text] [Related]
11. Bone mineral status, bone turnover markers and vitamin D status in children with congenital adrenal hyperplasia. Okten A, Cakir M, Makuloglu M. Minerva Endocrinol; 2012 Sep 25; 37(3):275-82. PubMed ID: 22766894 [Abstract] [Full Text] [Related]
12. Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia. Falhammar H, Filipsson Nyström H, Wedell A, Brismar K, Thorén M. Eur J Endocrinol; 2013 Mar 25; 168(3):331-41. PubMed ID: 23211577 [Abstract] [Full Text] [Related]
13. Growth and development in children with classic congenital adrenal hyperplasia. Bonfig W. Curr Opin Endocrinol Diabetes Obes; 2017 Feb 25; 24(1):39-42. PubMed ID: 27898585 [Abstract] [Full Text] [Related]
14. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. Girgis R, Winter JS. J Clin Endocrinol Metab; 1997 Dec 25; 82(12):3926-9. PubMed ID: 9398689 [Abstract] [Full Text] [Related]
15. Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: in early infancy and (pre)puberty. Stikkelbroeck NM, Van't Hof-Grootenboer BA, Hermus AR, Otten BJ, Van't Hof MA. J Clin Endocrinol Metab; 2003 Aug 25; 88(8):3525-30. PubMed ID: 12915631 [Abstract] [Full Text] [Related]
16. Hydrocortisone treatment in girls with congenital adrenal hyperplasia inhibits serum dehydroepiandrosterone sulfate and affects the GH-IGF-I system. Guercio G, Rivarola MA, Chaler E, Maceiras M, Belgorosky A. J Pediatr Endocrinol Metab; 2009 Mar 25; 22(3):255-61. PubMed ID: 19492582 [Abstract] [Full Text] [Related]
17. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Manoli I, Kanaka-Gantenbein Ch, Voutetakis A, Maniati-Christidi M, Dacou-Voutetakis C. Clin Endocrinol (Oxf); 2002 Nov 25; 57(5):669-76. PubMed ID: 12390343 [Abstract] [Full Text] [Related]
18. Growth impairment in a boy with late-onset congenital adrenal hyperplasia and anorexia nervosa. Niedziela M, Sippell W. Exp Clin Endocrinol Diabetes; 2010 Mar 25; 118(3):180-3. PubMed ID: 20198557 [Abstract] [Full Text] [Related]
19. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. Quintos JB, Vogiatzi MG, Harbison MD, New MI. J Clin Endocrinol Metab; 2001 Apr 25; 86(4):1511-7. PubMed ID: 11297576 [Abstract] [Full Text] [Related]
20. Lipid profile in congenital adrenal hyperplasia. Botero D, Arango A, Danon M, Lifshitz F. Metabolism; 2000 Jun 25; 49(6):790-3. PubMed ID: 10877208 [Abstract] [Full Text] [Related] Page: [Next] [New Search]